Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, February 27 2017 10:19am ET - U.S. Markets close in 5 hours and 41 minutes.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Sunday, Feb 26, 2017
·Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Business Wire - Sun 12:30 pm ET
Saturday, Feb 25, 2017
·Pfizer subpoenaed in U.S. over patient assistance plans
Reuters - Fri Feb 24
·Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
Bloomberg - Fri Feb 24
·Pfizer’s Valuation after Its 4Q16 Earnings Release
- Fri Feb 24
·Vietnam Wall education center gets a big cash gift but is still short more than $80M
at bizjournals.com - Fri Feb 24
·In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Business Wire - Fri Feb 24
Friday, Feb 24, 2017
·Pfizer Prices $1,065,000,000 Debt Offering
Business Wire - Fri Feb 24
·Merck Takes $2.9 Billion Charge on Dampened Outlook for Hepatitis Drug
at TheStreet.com - Fri Feb 24
·Novartis Lung Cancer Drug Combo Gets CHMP Nod
at Investopedia - Fri Feb 24
·Novartis Cancer Drug Zykadia Gets Priority Review
at Investopedia - Fri Feb 24
·Merck Antiviral Drug Reports Positive Data
at Investopedia - Fri Feb 24
·Eli Lilly & Co.’s Cardiovascular Franchise
- Fri Feb 24
·Wall Street Analysts’ Estimates for Merck & Co.
- Fri Feb 24
·Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; stable outlook
- Fri Feb 24
·Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline
PR Newswire - Fri Feb 24
·Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen
CNW Group - Fri Feb 24
·Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer
- Fri Feb 24
·Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines
Business Wire - Fri Feb 24
·The Demise Of The Erectile Dysfunction TV Ads
at Forbes.com - Fri Feb 24
·Performance of Eli Lilly & Co.’s Business Segments in 4Q16
- Fri Feb 24
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?